The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of new CEO

6 Dec 2021 07:00

RNS Number : 6050U
Cellular Goods PLC
06 December 2021
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press Release

6 December 2021

 

Cellular Goods PLC

("Cellular Goods" or "The Company") 

 

Appointment of new Chief Executive Officer

 

 

The Board of Cellular Goods plc is pleased to announce the appointment of Anna Chokina as Chief Executive Officer and Director to drive the Company's next stage of growth following the launch of its inaugural product range on 1 December 2021.

 

Anna succeeds Alexis Abraham, who becomes Chief Strategy Officer, and both appointments take effect from 6 December 2021.

 

Anna is a highly successful and experienced executive having spent more than 20 years in senior level roles in the fast-moving consumer goods industry. She was previously the Vice President of Global Colour Cosmetics, Global Face Care and Personal Care at Avon where she established a solid track record of implementing business transformation in a competitive environment. Moreover, during her tenure at Avon, Anna successfully launched Avon's first-ever lines of cannabidiol (CBD) based products for the personal care and skincare market. Prior to that Anna was General Manager of L'Oreal Paris for Russia, delivering three consecutive years of growth despite an economic recession.

 

Her other previous senior roles included leading the $800 million snacks portfolio for PepsiCo Russia and, prior to that, a decade managing large portfolios for Procter & Gamble including feminine hygiene, healthcare and pet care in both the US and the UK.

 

Alexis, who has served as Chief Executive Officer since February 2021, successfully led the Company through its first stage of development, its flotation on the London Stock Exchange and the launch of its first range of skincare and ingestibles in less than a year. In his new role Alexis will be focussing on brand positioning and product development. He remains a Director on the Board.

Peter Wall, Chairman of Cellular Goods, said: "On behalf of the Board, I would like to thank Alexis for his hard work and ongoing commitment to Cellular Goods. Under his leadership the Company has established a strong foundation as the first pure-play consumer cannabinoid brand to list on the LSE and successfully launched its inaugural product ranges just nine months after the start-up of commercial operations.

"Anna's appointment heralds an exciting new chapter for Cellular as the Company enters its revenue generating phase and her deep expertise will help guide the future direction of the Company. She has a proven track record with several global consumer brands and is the right leader to drive Cellular to the next level. Our ambition for the Company is significant and clear and the entire Company and the Board look forward to working with her."

Anna Chokina, Chief Executive of Cellular Goods, commented: "I am excited to join Cellular Goods at this point of development, following the launch of its inaugural product range. I am proud to be joining a company that produces high-quality, research-backed products and that champions the use of innovative and sustainable lab-made cannabinoids. I believe there is a significant opportunity to harness the strengths of the business to successfully deliver the planned product expansion and brand elevation. I am looking forward to working with the whole Cellular team to build a strong business for our customers, our employees, our partners and to deliver long-term value for our shareholders."

Alexis Abraham, Chief Strategy Officer of Cellular Goods, said: "I am immensely proud to have been able to realise our growth strategy in a far shorter time period than anticipated and am delighted to pass the baton to Mrs Chokina. Last week we launched our inaugural products and Cellular Goods is ideally positioned to become the leading player in the space".

For further information please contact:

Cellular Goods

Anna Chokina

Chief Executive

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Edward Daly

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 786 143 0057

+44 789 755 7112

 

 

About Cellular Goods PLC

 

Cellular Goods is a U.K.-based provider of premium consumer products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. The initial focus is on three product verticals: premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website.

 

www.cellulargoods.co 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOATFBMTMTMMMAB
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.